Facebook
Twitter
LinkedIn
Forward2020 Pediatric Grand Rounds | Targeted Delivery of Therapeutic Peptides Using Supramolecular Nanomaterials to Drug Intercellular Protein-Protein Interactions in Cancer
Molecular engineering has only recently solved many issues regarding stable drug delivery of non-soluble compounds. Ideal treatments would harness the theoretical power of nanodrug delivery and packaging with meaningful biologic purpose. This is arguably just beginning to occur and the future remains bright for more potent drugs targeting a wide array of protein-protein interactions within a cell.
Despite a veritable "treasure trove" of promising pre-clinical therapeutic peptides, their clinical translation has been hampered by an inability to deliver them specifically to target cells and to insert them into the cytosol. This has limited the ability to push the therapeutic boundaries against refractory tumors using synthetic compounds because of off-target effects. Widening the therapeutic window of these drugs should allow for more potent efficacy. The limitation deficit has been how to effectively do this in a clinically meaningful way.
Target Audience
Pediatric Hematology/Oncology Physicians, Advance Practice Practitioners, staff and research team.
Learning Objectives
- Demonstrate the importance and difficulties in drugging intracellular protein-protein interactions.
- Examine the impact of hydrocarbon stapling on alpha-helical peptides and their use as molecular mimics.
- Outline the therapeutic impact of first priming a cancerous cell to be more sensitive to targeted therapies.
Additional Information
| Attachment | Size |
|---|---|
 AB1195 Bibliography | 81.87 KB |
Virtual Meeting- Zoom
James LaBelle, MD, PhD Associate Professor of Pediatrics; Director, Pediatric Stem Cell and Cellular Therapy Program; University of Chicago
Dr. LaBelle has indicated that he receives Grant/Research Support from AbbVie; is a Consultant for AbbVie; and is on the Speakers Bureau for KITE Pharma.
Dr. LaBelle will be discussing the off-label or investigational use of ABT-199 (venetoclax), ABT-263 (navitoclax), S63845, A-1331852.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
Available Credit
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2020 Pediatric Grand Rounds | Targeted Delivery of Therapeutic Peptides Using Supramolecular Nanomaterials to Drug Intercellular Protein-Protein Interactions in Cancer for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity. - 1.00 Attendance